Sage Therapeutics (NASDAQ:SAGE) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sage ...

The market expects Sage Therapeutics, Inc. (SAGE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago.

In the last three months, 4 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

SAGE THERAPEUTICS ($SAGE) posted quarterly earnings results on Tuesday, April 29th. The company reported earnings of -$1.01 per share, beating estimates of -$1.04 by ...

BofA withdrew its rating on SAGE in January after the depression drug developer said that Biogen (NASDAQ:BIIB) agreed to buy ...

$50,000 of SAGE THERAPEUTICS lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Education and awareness of mental health ...

In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Equities researchers at Wedbush issued their Q1 2026 earnings estimates for Sage Therapeutics in a report released on Wednesday ...

The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Needham on April 30, 2025. The analyst firm set a price target for $0.00 expecting SAGE to fall to within 12 months (a ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...